Biohaven Ltd. (NYSE:BHVN) has announced major breakthroughs with its novel precision immunology therapies, BHV-1400 and BHV-1300, at its 2025 R&D Day in New Haven. BHV-1400, a first-in-class TRAP degrader, achieved up to 81% reduction in galactose-deficient IgA1 (Gd-IgA1), the key driver of IgA nephropathy (IgAN), after a single subcutaneous dose, with effects lasting for weeks.
A patient viewing their medical diagnosis on a digital healthcare ecosystem.
Unlike traditional immunosuppressive treatments, BHV-1400 precisely eliminates pathogenic Gd-IgA1 while sparing healthy antibodies (IgA, IgG, IgE, IgM), preserving overall immune function and offering a superior safety profile. This selectivity sets it apart from complement and BLyS/APRIL inhibitors, which can compromise broader immunity. Encouraged by these results, Biohaven Ltd. will launch a pivotal IgAN trial in 2026 using the urine protein-creatinine ratio as an accelerated approval endpoint.
Simultaneously, BHV-1300, targeting IgG-mediated diseases like Graves’ Disease, demonstrated rapid, deep, and sustained total IgG reductions of up to 87% in Phase 1, with flexible dosing for acute and chronic management. Both therapies were well-tolerated, with no serious adverse events.
Biohaven Ltd. plans pivotal trials for BHV-1300 in Graves’ Disease in the second half of 2025, reinforcing its leadership in precision immunology.
READ NEXT: 10 Best Cancer Stocks to Invest in for Long-Term Gains and 10 Most Oversold Stocks to Buy According to Billionaires.
